company background image
GTBP

GT Biopharma NasdaqCM:GTBP Stock Report

Last Price

US$2.79

Market Cap

US$85.1m

7D

-4.8%

1Y

-74.9%

Updated

06 Aug, 2022

Data

Company Financials +
GTBP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GTBP Stock Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

GT Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GT Biopharma
Historical stock prices
Current Share PriceUS$2.79
52 Week HighUS$11.32
52 Week LowUS$1.51
Beta0.44
1 Month Change-11.71%
3 Month Change68.07%
1 Year Change-74.89%
3 Year Change-8.82%
5 Year Change-98.96%
Change since IPO-100.00%

Recent News & Updates

Jun 08
Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

GTBPUS BiotechsUS Market
7D-4.8%5.7%1.0%
1Y-74.9%-24.5%-12.9%

Return vs Industry: GTBP underperformed the US Biotechs industry which returned -24.5% over the past year.

Return vs Market: GTBP underperformed the US Market which returned -12.8% over the past year.

Price Volatility

Is GTBP's price volatile compared to industry and market?
GTBP volatility
GTBP Average Weekly Movement13.3%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: GTBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: GTBP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19658Michael Breenhttps://www.gtbiopharma.com

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.

GT Biopharma Fundamentals Summary

How do GT Biopharma's earnings and revenue compare to its market cap?
GTBP fundamental statistics
Market CapUS$85.10m
Earnings (TTM)-US$33.78m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GTBP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$33.78m
Earnings-US$33.78m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.11
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GTBP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is GTBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GTBP?

Other financial metrics that can be useful for relative valuation.

GTBP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does GTBP's PB Ratio compare to its peers?

GTBP PB Ratio vs Peers
The above table shows the PB ratio for GTBP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.4x
JSPR Jasper Therapeutics
1.3x-15.3%US$85.4m
SLDB Solid Biosciences
0.5x-9.8%US$85.6m
PYXS Pyxis Oncology
0.4x-15.2%US$84.3m
GTH Genetron Holdings
0.6xn/aUS$86.0m
GTBP GT Biopharma
4.8x-44.7%US$85.1m

Price-To-Book vs Peers: GTBP is expensive based on its Price-To-Book Ratio (4.8x) compared to the peer average (4.4x).


Price to Earnings Ratio vs Industry

How does GTBP's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: GTBP is expensive based on its Price-To-Book Ratio (4.8x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is GTBP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GTBP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GTBP's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of GTBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GTBP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GTBP's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is GT Biopharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-44.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GTBP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GTBP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GTBP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GTBP is forecast to have no revenue next year.

High Growth Revenue: GTBP is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GTBP's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has GT Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


22.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GTBP is currently unprofitable.

Growing Profit Margin: GTBP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GTBP is unprofitable, but has reduced losses over the past 5 years at a rate of 22.1% per year.

Accelerating Growth: Unable to compare GTBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).


Return on Equity

High ROE: GTBP has a negative Return on Equity (-189.87%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is GT Biopharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GTBP's short term assets ($27.2M) exceed its short term liabilities ($9.5M).

Long Term Liabilities: GTBP's short term assets ($27.2M) exceed its long term liabilities ($147.0K).


Debt to Equity History and Analysis

Debt Level: GTBP is debt free.

Reducing Debt: GTBP currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GTBP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GTBP has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.4% each year.


Discover healthy companies

Dividend

What is GT Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GTBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GTBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GTBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GTBP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GTBP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Michael Breen (59 yo)

0.42

Tenure

US$2,827,703

Compensation

Mr. Michael Martin Breen serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as Executive Chairman at GT Biopharma, Inc. since November 08, 2021 and serve...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD2.83M) is above average for companies of similar size in the US market ($USD767.72K).

Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.


Leadership Team

Experienced Management: GTBP's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: GTBP's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.4%.


Top Shareholders

Company Information

GT Biopharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: GT Biopharma, Inc.
  • Ticker: GTBP
  • Exchange: NasdaqCM
  • Founded: 1965
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$85.097m
  • Shares outstanding: 30.50m
  • Website: https://www.gtbiopharma.com

Number of Employees


Location

  • GT Biopharma, Inc.
  • 8000 Marina Boulevard
  • Suite 100
  • Brisbane
  • California
  • 94005
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.